Identification of Novel Small Molecule Ligands for JAK2 Pseudokinase Domain

Identification of Novel Small Molecule Ligands for JAK2 Pseudokinase Domain

Hyperactive mutation V617F in the JAK2 regulatory pseudokinase domain (JH2) is prevalent in patients with myeloproliferative neoplasms. Here, we identified novel small molecules that target JH2 of JAK2 V617F and characterized binding via biochemical and structural approaches. Screening of 107,600 sm...

Full description

Bibliographic Details
Main Authors:	Anniina T. Virtanen, Teemu Haikarainen, Parthasarathy Sampathkumar, Maaria Palmroth, Sanna Liukkonen, Jianping Liu, Natalia Nekhotiaeva, Stevan R. Hubbard, Olli Silvennoinen
Format:	Article
Language:	English
Published:	MDPI AG 2023-01-01
Series:	Pharmaceuticals
Subjects:	JAK inhibitor JAK2 V617F myeloproliferative neoplasm cytokine signaling pseudokinase
Online Access:	https://www.mdpi.com/1424-8247/16/1/75

Similar Items

Hyperactivation of Oncogenic JAK3 Mutants Depend on ATP Binding to the Pseudokinase Domain
by: Juuli Raivola, et al.
Published: (2018-12-01)

THE JAK2V617F POINT MUTATION INCREASES THE OSTEOCLAST FORMING ABILITY OF MONOCYTES IN PATIENTS WITH CHRONIC MYELOPROLIFERATIVE NEOPLASMS AND MAKES THEIR OSTEOCLASTS MORE SUSCEPTIBLE TO JAK2 INHIBITION
by: Emmanouil Spanoudakis, et al.
Published: (2018-10-01)

JAK2V617F Allele Burden Measurement in Peripheral Blood of Iranian Patients with Myeloproliferative Neoplasms and Effect of Hydroxyurea on JAK2V617F Allele Burden
by: Shirin Ferdowsi, et al.
Published: (2016-04-01)

The C allele of <it>JAK2 </it>rs4495487 is an additional candidate locus that contributes to myeloproliferative neoplasm predisposition in the Japanese population
by: Ohyashiki Junko H, et al.
Published: (2012-01-01)

Thrombosis among 1537 patients with JAK2V617F‐mutated myeloproliferative neoplasms: Risk factors and development of a predictive model
by: Yuhui Zhang, et al.
Published: (2020-03-01)

Association of JAK2 Haplotype GGCC_46/1 with the Response to Onco-Drug in MPNs Patients Positive for JAK2V617F Mutation
by: Michela Perrone, et al.
Published: (2024-09-01)

JAK2-V617F Mutation Combined with Philadelphia Chromosome-Positive Chronic Myeloid Leukaemia: a Case Report
by: Mehrdad Payande, et al.
Published: (2011-06-01)

JAK2-V617F Mutation Combined with Philadelphia Chromosome-Positive Chronic Myeloid Leukaemia: a Case Report
by: Farhad Shaveisi Zadeh, et al.
Published: (2011-04-01)

A newly identified 45‐kDa JAK2 variant with an altered kinase domain structure represents a novel mode of JAK2 kinase inhibitor resistance
by: Sivahari Prasad Gorantla, et al.
Published: (2024-02-01)

Transient ischemic attacks as the first presentation of JAK2-V617F positive chronic myeloproliferative neoplasm
by: Fani Kalala, et al.
Published: (2012-06-01)

Discovery and evaluation of ZT55, a novel highly-selective tyrosine kinase inhibitor of JAK2V617F against myeloproliferative neoplasms
by: Min Hu, et al.
Published: (2019-02-01)

Gender and age characteristics of <I>JAK2</I> V617F mutation allelic burden and <I>CALR</I> and <I>MPL</I> driver mutations detection during primary examination of patients with suspected myeloproliferative neoplasms
by: I. A. Olkhovskiy, et al.
Published: (2024-12-01)

Evaluation of JAK2V617F mutation patients with non-CML myeloproliferative neoplasms by ARMS-PCR
by: F Nadali, et al.
Published: (2008-12-01)

Evaluation of JAK2V617F Mutation Patients with Non-CML Myeloproliferative Neoplasms by ARMS-PCR
by: K Alimoghaddam, et al.
Published: (2008-09-01)

Association of JAK2V617F mutation with thrombosis in Indian patients with Philadelphia negative chronic myeloproliferative neoplasms
by: Kanwaljeet Singh, et al.
Published: (2018-01-01)

Development of an enzyme-coupled activity assay for Janus kinase 2 inhibitor screening
by: Angelika Pölläniemi, et al.
Published: (2023-06-01)

Clinical Impact of JAK2V617F Allele Burden in Philadelphia-Negative Myeloproliferative Neoplasms
by: İpek Yonal Hindilerden, et al.
Published: (2023-08-01)

The Association Between JAK2V617F Mutation and Bone Marrow Fibrosis at Diagnosis in Patients with Philadelphia-Negative Chronic Myeloproliferative Neoplasms
by: M. Cem Ar, et al.
Published: (2012-08-01)

Evaluation of the JAK2V617F mutational burden in patients with philadelphia chromosome negative myeloproliferative neoplasms: A single-center experience
by: Popova-Labachevska M, et al.
Published: (2019-12-01)

Introducción del estudio molecular de la mutación JAK2V617F en neoplasias mieloproliferativas clásicas BCR-ABL negativas
by: Ana María Amor-Vigil, et al.

JAK2V617F Mutation in Endothelial Cells of Patients with Atherosclerotic Carotid Disease
by: Reyhan Diz Küçükkaya, et al.
Published: (2024-09-01)

JAK2 in Myeloproliferative Neoplasms: Still a Protagonist
by: Michael Stephan Bader, et al.
Published: (2022-01-01)

Laboratory-developed Droplet Digital PCR Assay for Quantification of the JAK2<sup>V617F</sup> Mutation
by: Yupeng Liu, et al.
Published: (2024-06-01)

The Association between Prevalence of JAK2V617F Mutation and Blood Indicies in Groups of Patients with Myeloproliferative Neoplasms in Rasul Akram Hospital
by: Mohsen Razavi, et al.
Published: (2011-10-01)

The Association between Prevalence of JAK2V617F Mutation and Blood Indicies in Groups of Patients with Myeloproliferative Neoplasms in Rasul Akram Hospital
by: Akram Asghari, et al.
Published: (2011-12-01)

Splenomegaly in myelofibrosis—new options for therapy and the therapeutic potential of Janus kinase 2 inhibitors
by: Randhawa Jasleen, et al.
Published: (2012-08-01)

Molecular basis of essential thrombocythaemia in humans and dogs – a review
by: Nicola Padzik, et al.
Published: (2021-03-01)

Rapid, low cost and sensitive detection of Calreticulin mutations by a PCR based amplicon length differentiation assay for diagnosis of myeloproliferative neoplasms
by: Ngo Tat Trung, et al.
Published: (2019-06-01)

The role of JAK2 abnormalities in hematologic neoplasms.
by: Mohammed Khalid Alabdulaali
Published: (2009-07-01)

Type II mode of JAK2 inhibition and destabilization are potential therapeutic approaches against the ruxolitinib resistance driven myeloproliferative neoplasms
by: Sivahari P. Gorantla, et al.
Published: (2024-07-01)

Chorea and Cognitive Impairment in JAK2V617F-Positive Myeloproliferative Disorders: A Case Report and Literature Review
by: Ioana Butnariu, et al.
Published: (2023-12-01)

THE ROLE OF JAK2 MUTATION IN THROMBOTIC COMPLICATIONS OF CHRONIC MYELOPROLIFERATIVE NEOPLASMS
by: Viola M. Popov, et al.
Published: (2014-08-01)

Frequency of JAK2 and MPL Mutation in BCR/ABL Negative Myelofibrosis in KPK
by: Ayesha Gul, et al.
Published: (2022-06-01)

Impact of CALR and JAK2V617F Mutations on Clinical Course and Disease Outcomes in Essential Thrombocythemia: A Multicenter Retrospective Study in Turkish Patients
by: Zehra Narlı Özdemir, et al.
Published: (2024-03-01)

PCR-HRM for Detecting JAK2V617F Gene Mutation: Is It a Sensitive Assay?
by: Mitra Rezaei, et al.
Published: (2020-04-01)

Tofacitinib Suppresses Several JAK-STAT Pathways in Rheumatoid Arthritis In Vivo and Baseline Signaling Profile Associates With Treatment Response
by: Maaria Palmroth, et al.
Published: (2021-09-01)

JAK2 V617F prevalence in Brazilian patients with polycythemia vera, idiopathic myelofibrosis and essential thrombocythemia
by: Bárbara da Costa Reis Monte-Mór, et al.
Published: (2007-03-01)

Case Report and Literature Review of Acute Spontaneous Intraspinal Epidural Hematoma (SSEH) Secondary to Myeloproliferative Disease
by: Liu Q, et al.
Published: (2024-05-01)

A mutação JAK2 V617F e as síndromes mieloproliferativas JAK2 V617F mutation and the myeloproliferative disorders
by: Bárbara C. R. Monte-Mór, et al.
Published: (2008-01-01)

Comparisions of ARMS-PCR and AS-PCR for the Evaluation of JAK2V617F Mutation in Patients with non-CML Myeloproliferative Neoplasms
by: Parisa Karimzadeh, et al.
Published: (2010-06-01)